Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Remus Pharmaceuticals IPO is a book build issue of ₹47.69 crores. The issue is entirely a fresh issue of 0.04 crore shares of ₹47.69 crore.
Remus Pharmaceuticals IPO bidding started from May 17, 2023 and ended on May 19, 2023. The allotment for Remus Pharmaceuticals IPO was finalized on May 24, 2023. The shares got listed on NSE SME on May 29, 2023.
Remus Pharmaceuticals IPO price band is set at ₹1229.00 per share . The lot size for an application is 100. The minimum amount of investment required by an retail is ₹1,15,000 (100 shares). The minimum lot size investment for HNI is 2 lots (200 shares), amounting to ₹2,45,800.
Beeline Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The market maker of the company is Sunflower Broking Pvt.Ltd..
Refer to Remus Pharmaceuticals IPO RHP for detailed Information.
| IPO Date | May 17, 2023 to May 19, 2023 |
| Listing Date | May 29, 2023 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹1150 to ₹1229 per share |
| Issue Price Final | ₹1229 per share |
| Lot Size | 100 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 3,88,000 shares (aggregating up to ₹47.69 Cr) |
| Reserved for Market Maker | 19,500 shares Sunflower Broking Pvt.Ltd. (aggregating up to ₹2.40 Cr) |
| Net Offered to Public | 3,68,500 shares (aggregating up to ₹45.29 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 10,85,000 shares |
| Share Holding Post Issue | 14,73,000 shares |
Remus Pharmaceuticals IPO offers total 3,88,000 shares. Out of which 1,84,200 (47.47%) allocated to QIB, 73,700 (18.99%) allocated to QIB, 55,300 (14.25%) allocated to NII, 1,29,000 (33.25%) allocated to RII and 1,10,500 (28.48%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 19,500 (5.03%) |
| QIB Shares Offered | 1,84,200 (47.47%) |
| − Anchor Investor Shares Offered | 1,10,500 (28.48%) |
| − QIB (Ex. Anchor) Shares Offered | 73,700 (18.99%) |
| NII (HNI) Shares Offered | 55,300 (14.25%) |
| Retail Shares Offered | 1,29,000 (33.25%) |
| Total Shares Offered | 3,88,000 (100.00%) |
Remus Pharmaceuticals IPO raises ₹13.58 crore from anchor investors. Remus Pharmaceuticals IPO Anchor bid date is May 16, 2023. Remus Pharmaceuticals IPO Anchor Investors list
| Bid Date | May 16, 2023 |
| Shares Offered | 1,10,500 |
| Anchor Portion Size (In Cr.) | 13.58 |
| Anchor lock-in period end date for 50% shares (30 Days) | June 23, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | August 22, 2023 |
Remus Pharmaceuticals IPO opens on May 17, 2023, and closes on May 19, 2023.
| IPO Open Date | Wed, May 17, 2023 |
| IPO Close Date | Fri, May 19, 2023 |
| Tentative Allotment | Wed, May 24, 2023 |
| Initiation of Refunds | Thu, May 25, 2023 |
| Credit of Shares to Demat | Fri, May 26, 2023 |
| Tentative Listing Date | Mon, May 29, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, May 19, 2023 |
Investors can bid for a minimum of 100 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹1,22,900 |
| Retail (Max) | 1 | 100 | ₹1,22,900 |
| HNI (Min) | 2 | 200 | ₹2,45,800 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 530.36 | 1,276.89 | 81.16 | 202.03 | 201.03 | 35.93 |
| 31-Mar-21 | 1,104.96 | 1,922.45 | 102.58 | 304.61 | 303.61 | 27.89 |
| 31-Mar-22 | 1,590.93 | 2,543.71 | 338.57 | 643.17 | 543.17 | 19.17 |
| 31-Dec-22 | 3,352.96 | 3,361.20 | 643.90 | 1,712.07 | 1,603.57 | 947.45 |
| Amount in ₹ Lakhs | ||||||
The market capitalization of Remus Pharmaceuticals IPO is ₹181.03 Cr.
| KPI | Values |
|---|---|
| ROE | 71.44% |
| ROCE | 69.99% |
| Debt/Equity | 0.03 |
| RoNW | 52.64% |
The Issue Proceeds from the Fresh Issue will be utilized towards the following objects:
[Dilip Davda] The company is in a highly competitive and fragmented segment of pharma product distribution with third-party contracts under the B2B model. Its profit margins are non-convincing. Based on super profits the issue appears fully priced. The sustainability of margins is a major concern. There is no harm in skipping this tricky issue that will have a longer gestation period for migration to the main board as post IPO its paid-up equity capital is just under Rs. 1.5 cr. Read detail review...
| Listing Date | May 29, 2023 |
| BSE Script Code | |
| NSE Symbol | REMUS |
| ISIN | INE0O5T01011 |
| Final Issue Price | ₹1229 per share |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹1,229.00 |
| Open | ₹1,711.25 |
| Low | ₹1,711.25 |
| High | ₹1,796.80 |
| Last Trade | ₹1,796.80 |
Remus Pharmaceuticals Ltd.
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad - 380054
Ahmedabad, Gujarat
Phone: +079- 2999 9857
Email: cs@remuspharma.com
Website: http://www.remuspharma.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Remus Pharmaceuticals IPO is a SME IPO of 3,88,000 equity shares of the face value of ₹10 aggregating up to ₹47.69 Crores. The issue is priced at ₹1229 per share. The minimum order quantity is 100.
The IPO opens on May 17, 2023, and closes on May 19, 2023.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Remus Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Remus Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Remus Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Remus Pharmaceuticals IPO opens on May 17, 2023 and closes on May 19, 2023.
Remus Pharmaceuticals IPO lot size is 100, and the minimum amount required for application is ₹1,22,900.
You can apply in Remus Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Remus Pharmaceuticals IPO will be done on Wednesday, May 24, 2023, and the allotted shares will be credited to your demat account by Friday, May 26, 2023. Check the Remus Pharmaceuticals IPO allotment status.
The Remus Pharmaceuticals IPO listing date is on Monday, May 29, 2023.
Useful Articles
RHP